Free On-line Access

SPCI - Sociedade Portuguesa de Cuidados Intensivos

Revista Brasileira de Terapia Intensiva

AMIB - Associação de Medicina Intensiva Brasileira

OFFICIAL JOURNAL OF THE ASSOCIAÇÃO BRASILEIRA DE MEDICINA INTENSIVA AND THE SOCIEDADE PORTUGUESA DE CUIDADOS INTENSIVOS

ISSN: 0103-507X
Online ISSN: 1982-4335

Ícone Fechar

How to Cite


 

Rojas H, Ritter C, Pizzol FD. Mecanismos de disfunção da barreira hematoencefálica no paciente criticamente enfermo: ênfase no papel das metaloproteinases de matriz. Rev Bras Ter Intensiva. 2011;23(2):222-227

 

 

2011;23(2):222-227
Review Article

http://dx.doi.org/10.1590/S0103-507X2011000200016

Mechanisms of dysfunction of the blood-brain barrier in critically ill patients: emphasis on the role of matrix metalloproteinases

Mecanismos de disfunção da barreira hematoencefálica no paciente criticamente enfermo: ênfase no papel das metaloproteinases de matriz

Hugo Rojas, Cristiane Ritter, Felipe Dal Pizzol

Experimental Pathophysiology Laboratory and National Institute for Medical Translational Science and Technology, Health Sciences Post-Graduation Program, Health Sciences Academic Unit, Universidade do Extremo Sul Catarinense - Criciúma (SC), Brazil

Conflicts of Interest: None.

Submitted on February 3, 2011
Accepted on May 17, 2011

Corresponding author:

Felipe Dal Pizzol
Laboratório de Fisiopatologia
Experimental, PPGCS, UNASAU
Universidade do Extremo Sul Catarinense
Zip Code: 88806-000 - Criciúma (SC), Brazil.
Fax: + 55 48 3443 4817
E-mail: [email protected]

 

Abstract

This paper aims to describe the physiological basis of the blood-brain barrier components and its properties. Additionally, the particular effects of metalloproteinases and their control over the extracellular matrix and its relationship with blood-brain barrier dysfunction are discussed. Finally, the role of metalloproteinases on changes in the central nervous system in critically ill patients is discussed.

Keywords: Blood-brain barrier; Extracellular matrix protein; Matrix metalloproteinases

 

 

INTRODUCTION

The concept of the blood-brain barrier (BBB) was initially presented at the end of the XIX century in Germany, based on Paul Ehrlich's studies where after injecting dyes into the arterial and venous circulation of animals, he observed that all organs except the spinal cord and brain were colored, leading him to hypothesize the existence of two compartments. In addition, in a review by Hugh Davson,(1) the studies of Bield and Kraus in 1989 and Lewandowsky in 1900 are mentioned, in which the lack of pharmacologic effects on the central nervous system (CNS) of systemically administered substances was ascribed to this barrier. Years later, in 1913, Edwin Goldmann (one of Ehrlich's students) observed the opposite phenomenon when he injected a dye directly into the cerebrospinal fluid of animals; this dye stained the entire CNS but not any peripheral organ.(2) In the 1960s, Reese and Karnovsky and Brightman and Reese repeated Ehrlich's and Goldman's experiments on a structural level using electronic microscopy and identified CNS capillary vessels and endothelial cells as the site of the blood-brain barrier.(1)

Blood-brain barrier (BBB)

BBB description

The central nervous system (CNS) is an area protected by three structural elements: the BBB, an interface between the brain and blood vessels; the blood-cerebrospinal fluid barrier (BCSFB), formed by the choroid plexus and arachnoid membrane along with blood vessels and cerebrospinal fluid; and the blood-arachnoid barrier (BAB), which is the interface between blood vessels and the arachnoid epithelium underlying the meningeal dura mater.(3) These barriers are specialized CNS structures regulating brain, spinal cord and cerebrospinal fluid homeostasis in relation with the remaining systems of the body.(4,5)

Components of the BBB

- Endothelial cells

The barrier is formed by endothelial junctions that control the coordinated opening and closing of cell-cell junctions.(6) The endothelial junctions are made up of different multi-protein complexes, including tight junctions (TJs) and adherens endothelial junctions (AEJs), which are the main cell permeability regulators.(7) TJs consist of three integral membrane proteins, claudin, occludin and junctional adhesion proteins, and a number of accessory cytoplasmic proteins, including zonula occludens (ZO) proteins 1, 2 and 3, cingulin, and other membrane-associated guanylate kinase (MAGUK) proteins. These accessory proteins connect membrane proteins to actin to maintain the integrity of endothelial structure and function. AEJs are made up of membrane proteins called cadherins that are connected to actin via intermediate proteins called catenins (α,β,) to form adhesive intracellular contacts and interact with TJs. Brain endothelial cells (BECs) lie over a basal lamina containing extracellular matrix molecules, covering more than 90% of the surface of the endothelial cells, and are involved in BBB permeability.(8,9)

- Occludins

Occludins were the first membrane proteins to be identified in endothelial cells TJs. Occludin is a 65 kDa phosphoprotein with four transmembrane domains and is connected to two extracellular tyrosine-rich moieties in the intracellular carboxy and terminal amino domains. The function of occludin should be mostly viewed in a regulatory context rather than as a relevant structural protein to establish the properties of the barrier. Its carboxy terminal cytoplasmic domain provides the connection between occludin and the cytoskeleton, providing high electrical resistance of endothelial cell monolayers and reducing the paracellular permeability.(10)

- Claudins

Claudins are 21-28 kDa integral proteins with four transmembrane domains, two extracellular loops and carboxy and amino terminal cytoplasmic domains with a short intracellular loop.(11,12) Extracellular moieties are bound to claudins of adjacent endothelial cells, forming the primary TJ fence.(11) The main role of claudins is the regulation of paracellular selectivity to small ions. To regulate this paracellular selectivity, the interactions between different classes occur in two distinct ways: laterally on the membrane level (heteromeric interactions) or head-to-head for adjacent cells (heterotypical interactions).(13,14)

- Astrocytes

In the human brain, astrocytes are star-shaped glial cells that are usually ten times more abundant than neurons,(15) and the extensions of astrocytes form a close and adhered lamellar net on the external BBB endothelial surface and respective basal membrane.(16) Increasingly, in vitro and in vivo data support the hypothesis that astrocytes are excitable cells and play a relevant role in information processing and neuron activity modulation.(17) These cells are important for vascular tonus control;(15) therefore, the role of astrocytes in the maintenance of brain microvasculature endothelial cells and in signaling has been studied in individuals with different diseases and in studies of BBB integrity.(18)

- Pericytes

Pericyte recruitment and endothelium interaction are essential for BBB formation, maturation and maintenance. Pericytes communicate directly with endothelial cells via invaginations called 'peg sockets', where one single pericyte may contact several endothelial cells, providing an additional communication layer(19) and mechanical stability for the vessels. Pericytes were shown in recent trials to be contractile brain cells that regulate the capillary blood flow, playing a relevant role in the maintenance of the BBB, along with brain homeostasis self-regulation.

In vivo studies have determined that the interactions of pericytes with endothelial cells are critical for BBB regulation, and disruption of these interactions may lead to barrier dysfunction and neuroinflammation.(20) Additionally, in vitro studies have shown that pericytes express molecules such as vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) that regulate the BBB integrity.(21)

- Extracellular matrix (ECM)

The extracellular space represents about 20% of the total brain volume and is filled with the highly organized extracellular matrix (ECM), which is located at the interface of the blood vessels and the glial cells. The ECM apparently acts as an endothelial anchor by interacting with integrin-type endothelial receptors,(7) which play a fundamental role in cell signaling, cell migration and brain capillary formation during angiogenesis.(9) These cell-matrix interactions may stimulate a series of intracellular signaling pathways in vascular cells, neurons and support glial cells and may additionally be essential to the BBB because they are likely to have a role in the maintenance of TJ endothelial proteins.(7,16,22)

ECM rupture may lead to changes in the cytoskeleton of brain microvasculature endothelial cells that in turn affect TJ proteins and barrier integrity, resulting in increased permeability in disease conditions.(16)

Blood-brain barrier functions

The BBB is an important part of the communication network connecting the CNS and peripheral tissues and additionally works as an interface limiting and regulating substance exchange between the blood and the CNS.(23)

BBB impermeability results from several unique features that make difficult for molecules trying to cross this barrier. This property is based on the extremely restrictive endothelial permeability and the high concentration of degrading enzymes within the endothelium. Because of this very limited permeability, except for water, gases such as oxygen and carbon dioxide and some very small liposoluble molecules can cross the barrier intact.(23) Hydrophilic molecules that are essential for brain metabolism, such as ions, glucose, amino acids and nucleic acid components, cross the BBB via specialized channels.(24) The transport of hydrophilic molecules, such as peptides and proteins that have no specific transport system, is much slower than for lipophilic molecules; however, the amounts crossing the BBB may be enough to cause a neuron-receptor-mediated effect. Some special proteins and peptides, such as peripheral hormones and regulatory brain-acting peptides, usually have their own specialized saturable systems all over the BBB. Therefore, the BBB is highly restrictive but is still unable to prevent some toxins and therapeutic agents from crossing from the blood stream into the brain.(24,25)

In addition to selective permeability, the BBB possesses relevant properties such as neuroimmune functions, including the secretion of cytokines, prostaglandins and nitric oxide. The BBB can be stimulated by one compartment (e.g., the systemic) and simultaneously respond with secretions to the other (e.g., the central nervous system); this function is central for the neuroimmune response. For example, LPS applied to the abluminal surface of endothelial brain cells stimulates IL-6 secretion from its luminal surface.(25)

Matrix metalloproteinases (MMP)

Extracellular matrix metalloproteinases are enzymes normally found in their inactive form. These proteins are part of the zinc-dependent proteinases family, with 23 members identified in humans to date.(26) These proteins are categorized as follows: a) true collagenases (MMP: 1, 8, 13), which digest triple-helix collagen; b) gelatinases (MMP: 2, 9), which act on collagen and denatured gelatin; c) stromelysins (MMP: 3, 10, 11), which degrade proteoglycans; d) matrilysins (MMP: 7, 26), which degrade proteoglycans, fibronectin and laminin; e) membrane-bound metalloproteinases or MT-MMPs (MMP: 14, 15, 16, 17, 23, 24, 25), in addition to other enzymes that catalyze the gelatin degradation of fibronectin, aggrecan and other ECM substrates; and f) other MMPs (MMP: 12, 19, 20, 21, 27 and 28),(27) which are able to degrade all EMC components and connective tissue proteins.(28)

MMP effects are strictly controlled by three mechanisms: (1) gene transcription regulation; (2) pro-enzymatic activation regulation; and (3) inhibition by specific molecules (TIMP).(27) MMP gene expression is controlled in response to cytokine (IL1, 4, 6 and TNFα) stimulation, reactive oxygen species (ROS), nitric oxide (NO), and hormones and growth factors that binding to cell surface receptors, triggering intracellular signaling cascades that, in turn, activate transcription factors that are bound to responsive regions on different MMP promotion genes.(29) MMPs are normally found inactive in the cytosol and may be cleaved by proteases such as plasmin, tissue plasminogen activator (tPA), or other MMPs into their active forms.(30) Endogenous tissue inhibitors of metalloproteinases (TIMP) are the main physiological MMP inhibitors; additionally, serum a-2 macroglobulin can inhibit the activity of MMPs. TIMPs are a group of proteins that are able to inhibit soluble MMPs in stoichiometric 1:1 ratios, forming TIMP-MMP complexes that render the protease unable to bind to the substrate. Currently, four TIMP family members are known, and MMPs may be inhibited by a number of different TIMPs.(30) Each TIMP has unique features: TIMP-1, TIMP-2 and TIMP-4 are in their soluble form, and TIMP-3 is strongly connected to the ECM(31). These inhibitors are related to cell growth promotion, synaptic plasticity and antiangiogenic and antiapoptotic activities.(32)

Blood-brain barrier dysfunction

BBB dysfunction, sometimes called 'BBB opening,' has been described to be central to CNS disease progression.(33) This dysfunction is probably related to exposure of the cerebral microenvironment to partially noxious substances, which may result in the loss of homeostasis, neuronal signaling or impairment and cell death.

The central role of MMPs in neurovascular matrix degradation and the genesis of different disease states have been shown in several neuroinflammation models. The activation and expression regulation of MMPs is complex and well controlled, and the loss of this control is involved in the BBB-disrupting pathophysiologies. After BBB disruption, neurotoxic substances are allowed to circulate into the brain parenchyma, with leukocyte infiltration and microglia activation, promoting the inflammatory response found in critically ill patients with different diseases, such as stroke and head trauma (HT).(16,34)

Studies in stroke animal models have demonstrated MMP activation, leading to basal lamina and ECM degradation with BBB disruption. This disruption leads to the increased frangibility of small vessels, contributing to the transition of an initially ischemic stroke into a hemorrhagic stroke. In addition, MMP-2 activation was observed in transient ischemic attack in the first steps of injury with consequent claudin degradation (part of the TJ structure, resulting in BBB disruption). MMP-9 is also apparently relevant in the acute phase in peri-infarction areas because it is related to neutrophil infiltration around capillary vessels, with worsened stroke-associated neuron death.(30,34) Although most investigations have focused on the functions of MMP-2 and MMP-9, other family members may also play relevant roles. For instance, MMP-3 may be activated post-brain ischemia/reperfusion in rats, causing ECM disruption and contributing to BBB opening, leading to neuroinflammation. Finally, MMP-13 was recently found in the brain of post-ischemic rats and was found in the nuclei of post-ischemic neuron cells and in hippocampal vessels, related to BBB disruption in stroke.(35,36) These changes could also be relevant to thrombolytic-associated brain bleeding. These therapeutic agents are associated with MMP activation, and, in animal models, pharmacologic MMP inhibition was able to reduce tPA-associated brain hemorrhage volumes.(37,38)

Post-mortem human studies have confirmed that MMP-9 is increased in the brain tissue in infarction and peri-infarction zones of stroke patients.(39) In a recent study, also in humans, an association between plasma MMP-9 levels and BBB disruption was found following stroke.(40) Together, cumulative experimental and clinical data suggest that MMPs may be a biomarker of neurovascular injury during the acute phase of stroke and suggest the use of tPA in conjunction with MMPs in patients eligible for thrombolysis.(37-41)

In animal HT model studies, increased MMP-9 levels were shown in cortical and hippocampal regions. MMP-2 was increased in this model days after the HT, suggesting an MMP activation cascade where fast MMP-9 activation(42) may be involved in sustained MMP-2 activation.(43) These changes are both temporally and spatially associated with BBB disruption and cerebral edema formation, and the use of MMP inhibitors leads to a reduced damage area and brain water leakage. In an HT model, MMP-9 transgenic mice showed significantly smaller injuries compared to wild-type mice. In addition to MMP-2 and -9, MMP-3 was also observed in an animal HT model, leading to vasogenic edema and consequent cell death.(44) Human studies found increased MMP-2 and MMP-9 levels in the plasma and brain during early the HT phase,(45) in addition to a close relationship between cytokines and increased acute-phase MMPs.(36,41,46-50)

In animal studies on status epilepticus induction, a hippocampal MMP-2 increase was found.(51,52) In the sera from children with status epilepticus, MMP-9 levels were found to be significantly higher and the levels of TIMP-1 inhibitors significantly lower when compared to the control patients, which could induce BBB dysfunction and brain edema.(53)

 

CLOSING REMARKS

Molecular neurobiology advances are quickly providing a better understanding of acute CNS changes in critically ill patients with different conditions. Our challenge is to precisely determine which MMP changes in critically ill patients are relevant for CNS dysfunction and how therapeutic interventions targeting these enzymes could contribute to BBB stabilization to mitigate neural dysfunctions.

 

REFERENCES

1. Davson H. Review lecture. The blood-brain barrier. J Physiol. 1976;255(1):1-28.

2. Wiesendanger M. Constantin von Monakow (1853-1930) and Lina Stern (1878-1968): early explorations of the plexus choroideus and the blood-brain-barrier. Schweizer Archiv für Neurologie und Psychiatrie. 2010;161(4):140-4.

3. Correale J, Villa A. Cellular elements of the blood-brain barrier. Neurochem Res. 2009;34(12):2067-77.

4. Banks WA. Characteristics of compounds that cross the blood-brain barrier. BMC Neurol. 2009;9 Suppl 1:S3.

5. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57(2):173-85

6. Stamatovic SM, Keep RF, Andjelkovic AV. Brain endothelial cell-cell junctions: how to "open" the blood brain barrier. Curr Neuropharmacol. 2008;6(3):179-92.

7. Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev. 2004;84(3):869-901. Review.

8. Bauer H, Zweimueller-Mayer J, Steinbacher P, Lametschwandtner A, Bauer HC. The dual role of zonula occludens (ZO) proteins. J Biomed Biotechnol. 2010;2010:402593.

9. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008; 57(2):178-201.

10. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol. 2006;1(3):223-36. Review.

11. Lal-Nag M, Morin PJ. The claudins. Genome Biol. 2009;10(8):235.

12. Furuse M. Molecular basis of the core structure of tight junctions. Cold Spring Harb Perspect Biol. 2010;2(1):a002907.

13. Findley MK, Koval M. Regulation and roles for claudin-family tight junction proteins. IUBMB Life. 2009;61(4):431-7.

14. Ohtsuki S, Sato S, Yamaguchi H, Kamoi M, Asashima T, Terasaki T. Exogenous expression of claudin-5 induces barrier properties in cultured rat brain capillary endothelial cells. J Cell Physiol. 2007;210(1):81-6.

15. Giaume C, Koulakoff A, Roux, L, Holcman D, Rouach N. Astroglial networks: a step further in neuroglial and gliovascular interactions. Nat Rev Neurosci. 2010;11(2): 87-99.

16. Cardoso FL, Brites D, Brito MA. Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches. Brain Res Rev. 2010;64(2):328-63.

17. Pereira A Jr, Furlan FA. Astrocytes and human cognition: modeling information integration and modulation of neuronal activity. Prog Neurobiol. 2010;92(3):405-20.

18. Willis CL, Nolan CC, Reith SN, Lister T, Prior MJ, Guerin CJ, et al. Focal astrocyte loss is followed by microvascular damage, with subsequent repair of the blood-brain barrier in the apparent absence of direct astrocytic contact. Glia. 2004;45(4):325-37.

19. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res. 2005;97(6):512-23. Review.

20. Daneman R, Zhou L, Kebede AA, Barres BA. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature. 2010;468(7323):562-6.

21. Thanabalasundaram G, Pieper C, Lischper M, Galla HJ. Regulation of the blood-brain barrier integrity by pericytes via matrix metalloproteinases mediated activation of vascular endothelial growth factor in vitro. Brain Res. 2010;1347:1-10

22. Zimmermann DR, Dours-Zimmermann MT. Extracellular matrix of the central nervous system: from neglect to challenge. Histochem Cell Biol. 2008;130(4):635-53.

23. Banks WA. Blood-brain barrier as a regulatory interface. Forum Nutr. 2010;63:102-10. Review.

24. Begley DJ, Brightman MW. Structural and functional aspects of the blood-brain barrier. Prog Drug Res. 2003;61:39-78.

25. Banks WA, Erickson MA. The blood-brain barrier and immune function and dysfunction. Neurobiol Dis. 2010;37(1):26-32.

26. Zhang H, Adwanikar H, Werb Z, Noble-Haeusslein LJ. Matrix metalloproteinases and neurotrauma: evolving roles in injury and reparative processes. Neuroscientist. 2010;16(2):156-70.

27. Wright JW, Harding JW. Contributions of matrix metalloproteinases to neural plasticity, habituation, associative learning and drug addiction. Neural Plast. 2009;2009:579382.

28. Kupai K, Szucs G, Cseh S, Hajdu I, Csonka C, Csont T, Ferdinandy P. Matrix metalloproteinase activity assays: Importance of zymography. J Pharmacol Toxicol Methods. 2010;61(2):205-9.

29. Sun J. Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells. J Signal Transuct. 2010;2010. pii: 985132.

30. Wang J. Preclinical and clinical research on inflammation after intracerebral hemorrhage. Prog Neurobiol. 2010;92(4):463-77.

31. Sekhon BS. Matrix metalloproteinases - an overview. Res Rep Biol. 2010;(1):1-20.

32. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta. 2010;1803(1):55-71.

33. Weiss N, Miller F, Cazaubon S, Couraud PO. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta. 2009;1788(4):842-57.

34. Candelario-Jalil E, Yang Y, Rosenberg GA. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience. 2009;158(3):983-94.

35. Solé S, Petegnief V, Gorina R, Chamorro A, Planas AM. Activation of matrix metalloproteinase-3 and agrin cleavage in cerebral ischemia/reperfusion. J Neuropathol Exp Neurol. 2004;63(4):338-49.

36. Rosell A, Alvarez-Sabín J, Arenillas JF, Rovira A, Delgado P, Fernández-Cadenas I, et al. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke. 2005;36(7):1415-20.

37. Arai K, Jin G, Navaratna D, Lo EH. Brain angiogenesis in developmental and pathological processes: neurovascular injury and angiogenic recovery after stroke. FEBS J. 2009;276(17):4644-52.

38. Morancho A, Rosell A, García-Bonilla L, Montaner J. Metalloproteinase and stroke infarct size: role for anti-inflammatory treatment? Ann N Y Acad Sci. 2010;1207:123-33.

39. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett. 1997;238(1-2):53-6.

40. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol. 1997;23(5):406-15.

41. Montaner J, Alvarez-Sabín J, Molina C, Anglés A, Abilleira S, Arenillas J, et al. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke. 2001;32(8):1759-66.

42. Hayashi T, Kaneko Y, Yu S, Bae E, Stahl CE, Kawase T, et al. Quantitative analyses of matrix metalloproteinase activity after traumatic brain injury in adult rats. Brain Res. 2009;1280:172-7.

43. Ding JY, Kreipke CW, Schafer P, Schafer S, Speirs SL, Rafols JA. Synapse loss regulated by matrix metalloproteinases in traumatic brain injury is associated with hypoxia inducible factor-1alpha expression. Brain Res. 2009;1268:125-34.

44. Donkin JJ, Vink R. Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments. Curr Opin Neurol. 2010;23(3):293-9. Review.

45. Vilalta A, Sahuquillo J, Rosell A, Poca MA, Riveiro M, Montaner J. Moderate and severe traumatic brain injury induce early overexpression of systemic and brain gelatinases. Intensive Care Med. 2008;34(8):1384-92.

46. Wang X, Jung J, Asahi M, Chwang W, Russo L, Moskowitz MA, et al. Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury. J Neurosci. 2000;20(18):7037-42.

47. Grossetete M, Phelps J, Arko L, Yonas H, Rosenberg GA. Elevation of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury. Neurosurgery. 2009;65(4):702-8.

48. Asahi M, Asahi K, Jung JC, del Zoppo GJ, Fini ME, Lo EH. Role of matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab. 2000;20(12):1681-9.

49. Suehiro E, Fujisawa H, Akimura T, Ishihara H, Kajiwara K, Kato S, et al. Increased matrix metalloproteinase-9 in blood in association with activation of interleukin-6 after traumatic brain injury: influence of hypothermic therapy. J Neurotrauma. 2004;21(12):1706-11.

50. Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke. 1998;29(10):2189-95.

51. Konopacki FA, Rylski M, Wilczek E, Amborska R, Detka D, Kaczmarek L, Wilczynski GM. Synaptic localization of seizure-induced matrix metalloproteinase-9 mRNA. Neuroscience. 2007;150(1):31-9.

52. Takács E, Nyilas R, Szepesi Z, Baracskay P, Karlsen B, Røsvold T, et al. Matrix metalloproteinase-9 activity increased by two different types of epileptic seizures that do not induce neuronal death: a possible role in homeostatic synaptic plasticity. Neurochem Int. 2010;56(6-7):799-809.

53. Suenaga N, Ichiyama T, Kubota M, Isumi H, Tohyama J, Furukawa S. Roles of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in acute encephalopathy following prolonged febrile seizures. J Neurol Sci. 2008;266(1-2):126-30.

 

 

Submission On-line

Indexed in

Scopus

SciELO

LILACS

Associação de Medicina Intensiva Brasileira - AMIB

Rua Arminda nº 93 - 7º andar - Vila Olímpia - São Paulo, SP, Brasil - Tel./Fax: (55 11) 5089-2642 | e-mail: [email protected]

Cookie Policy

GN1 - Systems and Publications